top of page
SCR101 topical skin product
Small molecule compound which has been safe in human for more than 30 years
Skin redness, including hypertrophic scar
QOL of post-surgical operation
Significant market size
Inhibition of neovascularization
Delivery to skin tissue
Efficient and rapid delivery
Acne: Clindamycin gel. SCR101 is differentiated from clindamycin gel.
Hypertrophic scar: No FDA approved drug
A US patent of SCR101 skin products has been issued in July, 2020.
bottom of page